Abstract
Objective
The aim of our study was to evaluate the clinical efficacy and side effects of docetaxel as single chemotherapy for elderly patients with advanced non-small-cell lung cancer (NSCLC).
Methods
Forty-two elderly patients with advanced NSCLC who were chemotherapy-naive were enrolled in this study. Docetaxel at the doses of 70 mg/m2 was administrated intravenously every 21 days as a cycle, each patient received 2–4 cycles. All patients were followed up until disease progressed or patients died.
Results
Among 42 patients, 40 could be evaluated, 1 complete response (CR), 9 partial response (PR), 13 stable disease (SD), 17 progress disease (PD). The overall response rate (CR + PR) was 35% and disease control rate (CR + PR + SD) was 57.5%. The median time to progress (TTP) was 4.2 months, median survival time was 6.1 months and 1-year survival rate was 35.8%. The main toxicity was myelosuppression and decreasing platelet.
Conclusion
Single agent docetaxel for elderly patients with advanced NSCLC is an efficient and well-tolerated chemotherapeutic approach with a low toxicity level.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Sorraritchingchai S, Thongprasert S, Charoentum C, et al. Treatment of advanced non-small cell lung cancer with vinorelbine in elderly Thai patients. J Med Assoc Thai, 2004, 87: 367–371.
Jatoi A, Stella PJ, Hillman S, et al. Weekly carboplatin and paclitaxel in elderly non-small-cell lung cancer patients (> or = 65 years of age): a phase II North Central Cancer Treatemt Group study. Am J Clin Oncol, 2003, 26: 441–447.
Spiro SG, Rudd RM, Souhami RL, et al. Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment quality of life. Thorax, 2004, 59: 828–836.
Saloustros E, Georgoulias V. Docetaxel in the treatment of advanced non-small-cell lung cancer. Expert Rev Anticancer Ther, 2008, 8: 1207–1222.
Feliu J, Firvida JL, Castro J, et al. Combination therapy with docetaxel and low dose of cisplatin in elderly patients with advanced non-small cell lung cancer: multicenter phase II study. Cancer Chemother Pharmacol, 2009, 63: 403–409.
Hesketh PJ, Lilenbaum RC, Chansky K, et al. Chemotherapy in patients > or = 80 with advanced non-small cell lung cancer: combined results from SWOG 0027 and LUN 6. J Thorac Oncol, 2007, 2: 494–498.
The elderly lung cancer vinorelbine Italian study group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst, 1999, 91: 66–72.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Cai, Y., Xie, X. & Li, M. Clinical observation of docetaxel in treating advanced non-small cell lung cancer in the elderly patients. Chin. -Ger. J. Clin. Oncol. 9, 201–203 (2010). https://doi.org/10.1007/s10330-010-0029-3
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10330-010-0029-3